title: Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
abstract: T cells expressing antigen-specific chimeric antigen receptors (CARs) improve outcomes for CD19-expressing B cell malignancies. We evaluated a human application of T cells that were genetically modified using the Sleeping Beauty (SB) transposon/transposase system to express a CD19-specific CAR.
  
  
  
  T cells were genetically modified using DNA plasmids from the SB platform to stably express a second-generation CD19-specific CAR and selectively propagated ex vivo with activating and propagating cells (AaPCs) and cytokines. Twenty-six patients with advanced non-Hodgkin lymphoma and acute lymphoblastic leukemia safely underwent hematopoietic stem cell transplantation (HSCT) and infusion of CAR T cells as adjuvant therapy in the autologous (n = 7) or allogeneic settings (n = 19).
  
  
  
  SB-mediated genetic transposition and stimulation resulted in 2,200- to 2,500-fold ex vivo expansion of genetically modified T cells, with 84% CAR expression, and without integration hotspots. Following autologous HSCT, the 30-month progression-free and overall survivals were 83% and 100%, respectively. After allogeneic HSCT, the respective 12-month rates were 53% and 63%. No acute or late toxicities and no exacerbation of graft-versus-host disease were observed. Despite a low antigen burden and unsupportive recipient cytokine environment, CAR T cells persisted for an average of 201 days for autologous recipients and 51 days for allogeneic recipients.
  
  
  
  CD19-specific CAR T cells generated with SB and AaPC platforms were safe, and may provide additional cancer control as planned infusions after HSCT. These results support further clinical development of this nonviral gene therapy approach.
  
  
  
  Autologous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT01492036.
  
  
  
  National Cancer Institute, private foundations, and institutional funds. Please see Acknowledgments for details.
authors.forename: Partow
authors.initials: P
authors.lastname: Kebriaei
authors.forename: Harjeet
authors.initials: H
authors.lastname: Singh
authors.forename: M Helen
authors.initials: MH
authors.lastname: Huls
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Figliola
authors.forename: Roland
authors.initials: R
authors.lastname: Bassett
authors.forename: Simon
authors.initials: S
authors.lastname: Olivares
authors.forename: Bipulendu
authors.initials: B
authors.lastname: Jena
authors.forename: Margaret J
authors.initials: MJ
authors.lastname: Dawson
authors.forename: Pappanaicken R
authors.initials: PR
authors.lastname: Kumaresan
authors.forename: Shihuang
authors.initials: S
authors.lastname: Su
authors.forename: Sourindra
authors.initials: S
authors.lastname: Maiti
authors.forename: Jianliang
authors.initials: J
authors.lastname: Dai
authors.forename: Branden
authors.initials: B
authors.lastname: Moriarity
authors.forename: Marie-Andrée
authors.initials: MA
authors.lastname: Forget
authors.forename: Vladimir
authors.initials: V
authors.lastname: Senyukov
authors.forename: Aaron
authors.initials: A
authors.lastname: Orozco
authors.forename: Tingting
authors.initials: T
authors.lastname: Liu
authors.forename: Jessica
authors.initials: J
authors.lastname: McCarty
authors.forename: Rineka N
authors.initials: RN
authors.lastname: Jackson
authors.forename: Judy S
authors.initials: JS
authors.lastname: Moyes
authors.forename: Gabriela
authors.initials: G
authors.lastname: Rondon
authors.forename: Muzaffar
authors.initials: M
authors.lastname: Qazilbash
authors.forename: Stefan
authors.initials: S
authors.lastname: Ciurea
authors.forename: Amin
authors.initials: A
authors.lastname: Alousi
authors.forename: Yago
authors.initials: Y
authors.lastname: Nieto
authors.forename: Katy
authors.initials: K
authors.lastname: Rezvani
authors.forename: David
authors.initials: D
authors.lastname: Marin
authors.forename: Uday
authors.initials: U
authors.lastname: Popat
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Michael
authors.initials: M
authors.lastname: Keating
authors.forename: William
authors.initials: W
authors.lastname: Wierda
authors.forename: Kim Anh
authors.initials: KA
authors.lastname: Do
authors.forename: David A
authors.initials: DA
authors.lastname: Largaespada
authors.forename: Dean A
authors.initials: DA
authors.lastname: Lee
authors.forename: Perry B
authors.initials: PB
authors.lastname: Hackett
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
authors.forename: Laurence J N
authors.initials: LJ
authors.lastname: Cooper
mesh_terms: D000328:Adult; D000938:Antigen-Presenting Cells / Q000276:immunology; D018941:Antigens, CD19 / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D004251:DNA Transposable Elements; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015316:Genetic Therapy / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D008213:Lymphocyte Activation / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D061214:Patient Safety; D010957:Plasmids / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018941:Antigens, CD19; D016207:Cytokines; D004251:DNA Transposable Elements; D011948:Receptors, Antigen, T-Cell